GCCA
14.3.2023 14:02:00 CET | Business Wire | Press release
Start-ups from around the world can play a leading role in helping an essential global industry in its efforts to cut CO2 emissions and help solve the climate challenge. They are being invited to apply for the Innovandi Open Challenge, an exciting international partnership programme, run by the Global Cement and Concrete Association (GCCA) and its member companies across the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005357/en/
Applications for the 2023 GCCA Innovandi Open Challenge are now open (Graphic: Business Wire)
Applicants are being asked to work on the development of new materials and ingredients for low carbon concrete – a major step towards the ultimate goal of net zero concrete.
Innovation can help further unlock the delivery of low carbon concrete by reducing the amount of clinker used - the carbon intensive element of cement - or by using the most cutting-edge manufacturing processes. Alternative materials, including construction and demolition waste, can result in much lower CO2 emissions than concrete made in the traditional method, as well as reduce the need to use virgin raw materials.
The global challenge matches start-up companies with some of the world’s leading cement and concrete manufacturers, who operate in almost every country across the world, to work on initiatives to cut emissions and pioneer environmental change across the industry.
The GCCA and its members account for 80% of global cement production capacity outside of China, as well as some key Chinese manufacturers. Member companies have committed to reducing and ultimately eliminating CO2 emissions in concrete (which currently account for around 7% globally), through implementation of the GCCA’s Concrete Future 2050 Net Zero Roadmap – the first heavy industry to set out such a detailed plan.
The launch follows the success of last year’s first ever Innovandi Open Challenge, which saw cement companies partnering with six start-ups, with a strong focus on carbon capture and utilisation projects. Three of those projects have already gone to pilot stage.
Thomas Guillot, Chief Executive of the GCCA, said:
“We’re calling on the best and the brightest from around the world to join us in the urgent fight to limit global warming and help towards delivering the great prize of net zero concrete. If you are a start up from Austria to Australia, from Brazil to Bangladesh, with an innovative idea or technology, then we want to hear from you.”
“Concrete is the second most used substance on earth after water and is a vital part of our modern infrastructure. The GCCA and all our members are working hard to reduce emissions. And start-ups can play a big role in helping us to do that.”
Start-ups can find more information and apply to take part in the Innovandi Open Challenge by going to the GCCA Open Challenge webpage:
https://gccassociation.org/innovandi/openchallenge/oc2023
Those companies who are accepted for this year’s Innovandi Open Challenge, will gain unique access to industry plants, labs, key networks and the expertise and infrastructure of the GCCA’s 40 members from around the world. They will also receive guidance from the GCCA and its members to help them with the development of new technology and business cases.
Claude Loréa, GCCA Cement Director and Innovation Lead said:
“We’ve already seen some remarkable progress from those start-ups who’ve been working with our members on the first Innovandi Open Challenge, with several projects already in the pilot stage. This year’s theme, low carbon concrete, is equally challenging. To succeed, we need products which are affordable, scalable, and easily adopted. Good luck to all this year’s applicants. We look forward to working with those selected.”
Natalie Giglio is Senior Business Development Associate, at Carbon Upcycling Technologies in Canada, which took part in the first Innovandi Open Challenge. She encourages all start-ups interested in working on net-zero initiatives to apply:
"The Innovandi program is specifically designed to foster collaboration among the largest global cement producers, and start-ups, which is an opportunity unique to this challenge. Our initiative focused on validating materials at the lab scale, and now the results have set a foundation for further collaboration and project development.”
/ Ends
Notes to editors:
The Innovandi Open Challenge is open to applicants from 14th March 2023, with applications closing on 30th May 2023.
For more information click here:
Additional quotes from start-ups which have taken part in the 1st Innovandi Open Challenge:
Carbon BioCapture is based in the USA and has patented technology for CO2 capture using microalgae (microscopic algae invisible to the naked eye.) CEO Andrea Irarrazaval said: “It has been a great opportunity and an honour for Carbon BioCapture (CBC) to be selected in GCCA's Open Challenge global programme… Participation provides valuable means for tech start-ups to access, obtain growth assistance, and help to demonstrate their technology potential to the critical cement and concrete global industry."
CarbonOrO, based in the Netherlands, specializes in carbon capture technology using unique bi-phasic amine. Spokesperson Jan Hoppenbrouwers said: “There is a lot of talk about carbon capture, utilisation and storage but worldwide, we need to accelerate the number of pilots and move towards commercial scale roll-out. GCCA members and their consortia’s joined efforts have all the characteristics to change this. So, our advice, participate in this challenge.”
Coomtech based in the UK, has developed a low energy, low cost drying technology using managed turbulent air, creating kinetic energy to remove moisture. Founder Chris Every said: “Coomtech took part in the Innovandi Open Challenge to showcase its technology at a global level to the cement and concrete industry. Innovandi has been highly supportive and is commercially attuned to new technologies. The connections the program makes are an excellent springboard for emerging technology businesses focused on the vital cement and concrete sector.”
Fortera, based in the USA, uses technology to capture CO2 emissions from cement plants, combining it with calcium oxide to make reactive calcium carbonate. Vice President Kas Farsad, said: “The Innovandi Open Challenge platform allowed Fortera to engage multiple cement players simultaneously and really dig into not just industry pain points, but brainstorm on solutions with the broader industry in mind. Whether you're looking to launch a pilot plant or to validate a commercial offering, you'll get a committed consortium of GCCA members supporting your process."
MOF Technologies, based in the UK, is using modern sorbents called metal-organic frameworks (MOFs) to engineer a filtration system to capture and remove CO2 from flue gas. Conor Hamill, Co-CEO said: “Having developed a carbon capture system that overcomes the traditional adoption barriers of energy and cost, we are thrilled to have had the opportunity to collaborate with GCCA members to bring our technology to the field. We are currently working with an innovative consortium to pilot our ultra-efficient Nuada technology which will validate its potential to provide the industry with a scalable low-cost carbon capture solution.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005357/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release
Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co
Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press release
Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release
Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release
The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
